Hypha Discovery (U.K.)
Hypha Discovery is working with companies worldwide to deliver solutions to pharma and agrochemical clients through the scalable production of human and other mammalian metabolites for MetID, use as analytical standards and for DMPK and toxicological assays. Hypha’s scalable microbial platform has a high success rate in producing both difficult-to-synthesise Phase I oxidative metabolites as well as glucuronides, sulfates and other conjugates, and can be employed to deliver milligram to gram amounts of pure metabolites.
Hypha has also developed a successful platform for lead diversification and late stage functionalisation of compounds through aliphatic and aromatic hydroxylations. The technology enables the identification of active metabolites, improvement of solubility and provides handles for further derivatisation.